- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BMO initiates LB Pharmaceuticals stock at Outperform on drug data | 2 | Investing.com | ||
| Mo | LB Pharmaceuticals: BMO startet Coverage mit "Outperform" dank starker Studiendaten | 2 | Investing.com Deutsch | ||
| 10.07. | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| LB PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.07. | Wolfe Research initiates LB Pharmaceuticals stock with outperform rating | 4 | Investing.com | ||
| 30.06. | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | 407 | GlobeNewswire (Europe) | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| 22.06. | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | 2 | Investing.com | ||
| 09.06. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming June Investor Events | 1 | GlobeNewswire (USA) | ||
| 26.05. | Clear Street stuft LB Pharmaceuticals mit "Buy" ein und sieht Blockbuster-Potenzial | 1 | Investing.com Deutsch | ||
| 26.05. | Clear Street initiates LB Pharmaceuticals stock with buy rating | 1 | Investing.com | ||
| 26.05. | H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target | 1 | Investing.com | ||
| 26.05. | H.C. Wainwright bestätigt Kaufempfehlung für LB Pharmaceuticals mit Kursziel von 45 US-Dollar | - | Investing.com Deutsch | ||
| 12.05. | LB PHARMACEUTICALS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | 265 | GlobeNewswire (Europe) | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen | |
| 27.04. | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | 1 | Benzinga.com | ||
| 22.04. | LB Pharmaceuticals: Aktie nach positiven Studiendaten zu Schizophrenie-Mittel auf Höhenflug | 1 | Investing.com Deutsch | ||
| 22.04. | LB Pharmaceuticals publishes phase 2 schizophrenia trial results | 1 | Investing.com | ||
| 22.04. | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia | 1 | GlobeNewswire (USA) | ||
| 10.04. | Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating | 3 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,965 | +13,91 % | KURSZIEL ANGEHOBEN bei InnoCan Pharma: Hier baut sich gerade etwas Großes auf - Das sollten Sie jetzt wissen | ||
| JAGUAR HEALTH | 1,250 | -3,85 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
17.07.2026 / 17:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| KALA BIO | 0,745 | 0,00 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,340 | -1,18 % | Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer | ||
| GALECTIN THERAPEUTICS | 3,340 | -4,57 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,430 | -1,62 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,550 | +1,57 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,280 | -9,86 % | InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 | Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,600 | -1,14 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| MINDWALK | 1,230 | -3,15 % | H.C. Wainwright bestätigt Kaufempfehlung für MindWalk mit Kursziel 5 US-Dollar | ||
| LIPOCINE | 2,180 | -4,80 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,430 | +3,91 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| HARROW | 39,800 | +4,19 % | Samsung Bioepis, Harrow present SB11 biosimilar study results | ||
| INVENTIVA | 3,910 | -1,14 % | Cantor Fitzgerald initiates Inventiva stock with overweight rating | ||
| MEDICINOVA | 1,345 | -5,28 % | MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients | LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
Das Unternehmen LB PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,82 % bei einem Aktienkurs von 30,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LB PHARMACEUTICALS INC finden Sie auf Wallstreet Online.